u-Plasminogen Activator/Urokinase Antibody (901420) [Unconjugated]

Western blot shows lysates of mouse kidney tissue, mouse liver tissue, and mouse placenta tissue. PVDF membrane was probed with 1 µg/mL of Rat Anti-Mouse u-Plasminogen Activator (uPA)/Urokinase Monoclonal Antibody (Catalog # MAB9185) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005). A specific band was detected for u-Plasminogen Activator (uPA)/Urokinase at approximately 54 and 30 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

u-Plasminogen Activator (uPA)/Urokinase was detected in perfusion fixed frozen sections of mouse kidney using Rat Anti-Mouse u-Plasminogen Activator (uPA)/Urokinase Monoclonal Antibody (Catalog # MAB9185) at 25 µg/mL overnight at 4 °C. Tissue was stained using the NorthernLights™ 557-conjugated Anti-Rat IgG Secondary Antibody (red; Catalog # NL013) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm in convoluted tubules. View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

• Reactivity: Mu
• Applications: WB, IHC
• Clone: 901420
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

u-Plasminogen Activator/Urokinase Antibody (901420) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse uPA
  Met1-Phe433
  Accession # P06869
• Specificity: Detects mouse uPA in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-25 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to SDS for additional information and handling instructions.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for u-Plasminogen Activator/Urokinase Antibody (901420) [Unconjugated]

• ATF
• EC 3.4.21
• EC 3.4.21.73
• plasminogen activator, urokinase
• PLAU
• uPA
• u-PA
• uPlasminogen Activator
• u-Plasminogen Activator
• urinary
• Urokinase
• urokinase-type plasminogen activator

Background

Urokinase-type plasminogen activator (uPA) is a 378 amino acid enzyme which cleaves the zymogen plasminogen to form the active enzyme plasmin. uPa occurs in high and low molecular mass forms each consisting of two chains (A and B).  The high mass form has a long A chain while the low mass form has a short chain AuPA is widely expressed in normal tissues including epithelia, muscle, reproductive organs and brain, and  is highly expressed in kidney, where it localizes to proximal and distal tubules and is secreted into urine. uPA is known to play a role in wound healing and  tissue remodeling and  tumor invasion

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for u-Plasminogen Activator/Urokinase Antibody (MAB9185)(2)

Publications using MAB9185

• Ava P. Soleimany, Jesse D. Kirkpatrick, Susan Su, Jaideep S. Dudani, Qian Zhong, Ahmet Bekdemir et al. Activatable Zymography Probes Enable In Situ Localization of Protease Dysregulation in Cancer Cancer Research 2021-01-01 [PMID: 33106334] (Immunohistochemistry, Transgenic Mouse)
• M Krämer, P Markart, F Drakopanag, A Mamazhakyp, L Schaefer, M Didiasova, M Wygrecka Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system Cell. Signal., 2019-11-03;65(0):109432. 2019-11-03 [PMID: 31693876] (Western Blot, Human)

Bioinformatics

• Uniprot:
  • P06869()